And I should add, the same holds true for cancer (and the myriad other indications we are pursuing). We’ve already been given a free pass to Phase 2 whenever we want it because our safety profile has been fully established. Once the FDA acknowledges that we can reliably produce Leronlimab on a commercial scale, we only have to worry about the clinical portion for any future BLAs. The time and cost savings are enormous.